Validated antimalarial drug target discovery using genome-scale metabolic modeling.

Area of Science:

• Malariology
• Computational Biology
• Drug Discovery

Background:

• Plasmodium falciparum exhibits rapid resistance to existing antimalarial drugs, necessitating novel therapeutic strategies.
• Genome-scale metabolic (GSM) models offer a powerful approach to identify essential genes and potential drug targets in pathogens.

Purpose of the Study:

• To utilize a GSM model integrated with metabolomics and flux-balance data to predict essential genes in P. falciparum as novel drug targets.
• To validate the identified target, Plasmodium falciparum UMP-CMP kinase (UCK), for its essentiality and potential for inhibition.

Main Methods:

• Development of a genome-scale metabolic model for P. falciparum, incorporating metabolomics and constraint-based flux-balance data.
• CRISPR-Cas genome editing to create conditional deletion mutants of UCK using the DiCre recombinase system.
• In silico and in vitro screening to identify selective inhibitors of P. falciparum UCK with antiparasitic activity.

Main Results:

• Conditional deletion mutants of P. falciparum UCK demonstrated defective asexual growth and stage-specific developmental arrest.
• Selective inhibitors targeting P. falciparum UCK were identified, exhibiting significant antiparasitic activity.
• The study successfully validated P. falciparum UCK as a druggable target, demonstrating the utility of GSM models in drug discovery.

Conclusions:

• Genome-scale metabolic models can effectively identify and validate novel drug targets for antimalarial therapies.
• Plasmodium falciparum UMP-CMP kinase (UCK) is a validated and druggable target for the development of new antimalarial drugs.
• This research highlights a significant advancement in antimalarial drug discovery through integrated computational and experimental approaches.